Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.48 +1.03 (+2.42%)
Streaming Delayed Price Updated: 1:05 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
From Veracyte, Inc.
Via Business Wire
News headline image
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81 ↗
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
News headline image
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
News headline image
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View ↗
Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher... 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts ↗
 
Via Benzinga
News headline image
Recap: Veracyte Q4 Earnings ↗
 
Via Benzinga
News headline image
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
News headline image
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024 ↗
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Veracyte Announces Second Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
The 3 Best Personalized Nutrition Stocks to Buy Now ↗
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness ↗
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
News headline image
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 ↗
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Veracyte Announces First Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally ↗
On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares. 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
News headline image
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed ↗
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ: 
Via Benzinga
News headline image
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
News headline image
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 22, 2024 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.